9 completed, 3 terminated, 3 withdrawn, 1 active not recruiting. 17 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 9, Terminated 3, Withdrawn 3, Active not recruiting 1, Unknown 1 |
Follow Sulindac: new trials by email Literature Review of Sulindac trials Research Report on Sulindac
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40 Sulindac (HLX-0201), dose strength 1, Sulindac (HLX-0201), dose strength 2, Placebo - Fragile X Syndrome | Phase 2 | Withdrawn | Healx Limited | 2022-05-25 | 2022-12-08 | |
| Sulindac and Breast Density in Women at Risk of Developing Breast Cancer Sulindac Pill, Placebo - Breast Cancer | Phase 2 | Completed | Alison Stopeck | 61 | 2020-11-20 | 2026-07-17 |
| The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial) Sulindac 400 MG, Placebo - IPMN, IPMN, Pancreatic | Phase 2 | Active not recruiting | Duke University | 100 | 2020-07-10 | 2026-09-08 |
| Urinary Biomarker Study With Sulindac and Difluoromethylornithine difluoromethylornithine, Sulindac - Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms | Phase 2 | Withdrawn | Cancer Prevention Pharmaceuticals, Inc. | 2014-03-01 | 2014-07-30 | |
| Sulindac for Patients With AML Cytarabine, Sulindac - Acute Myeloid Leukemia | Phase 2 | Withdrawn | Massachusetts General Hospital | 2014-01-01 | 2017-02-17 | |
| Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer Sulindac, Placebo, Validate assays and shipping methods - Colorectal Cancer, Liver Metastasis | Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2013-04-01 | 2015-10-23 |
| NSAID Effects on Clinical and Imaging Breast Biomarkers Sulindac - Inflammation, Cancer | Phase 2 | Completed | Stony Brook University | 114 | 2012-12-01 | 2023-02-10 |
| A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients Erlotinib, Sulindac, Placebo A - Adenomatous Polyposis Coli | Phase 2 | Completed | University of Utah | 92 | 2010-04-01 | 2016-06-17 |
| Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma sulindac, placebo, laboratory biomarker analysis - Precancerous Condition | Phase 2 | Completed | National Cancer Institute (NCI) | 50 | 2009-02-01 | 2017-12-26 |
| Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma epirubicin hydrochloride, sulindac, immunologic technique - Melanoma (Skin) | Phase 2 | Completed | Cancer Trials Ireland | 32 | 2007-08-01 | 2014-12-31 |
| Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck Bevacizumab, erlotinib, Sulindac - Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Terminated | Massachusetts General Hospital | 36 | 2006-10-01 | 2017-04-13 |
| Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia sulindac, placebo - Precancerous Condition, Stage I Non-small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 61 | 2006-08-01 | 2014-05-23 |
| Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis Sulindac (drug), VSL#3 (probiotic), Inulin (probiotic) - Adenomatous Polyposis Coli | Phase 2 | Unknown | Radboud University Medical Center | 30 | 2006-04-01 | 2007-08-10 |
| Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia oligofructose-enriched inulin, sulindac, placebo - Colon Cancer, Precancerous Condition | Phase 2 | Completed | National Cancer Institute (NCI) | 85 | 2006-03-01 | 2017-02-15 |
| Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor tamoxifen citrate, sulindac, laboratory biomarker analysis - Desmoid Tumor | Phase 2 | Completed | Children's Oncology Group | 70 | 2004-02-01 | 2020-02-19 |
| Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer Acetylsalicylic acid (Aspirin), Sulindac, Ursodiol - Colorectal Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 12 | 2003-06-01 | 2012-07-30 |
| Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer docetaxel, sulindac - Breast Cancer | Phase 2 | Completed | Fox Chase Cancer Center | 10 | 2002-01-01 | 2014-05-06 |
Breast Neoplasms (3) · Precancerous Conditions (3) · Adenomatous Polyposis Coli (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Desmoid Tumors (1) · Fragile X Syndrome (1) · Hypertension (1) · Inflammation (1) · Leukemia, Myeloid, Acute (1) · Melanoma (1) · Pain (1) · Pancreatic Intraductal Neoplasms (1)
National Cancer Institute (NCI) (4) · Massachusetts General Hospital (2) · Alison Stopeck (1) · Cancer Prevention Pharmaceuticals, Inc. (1) · Cancer Trials Ireland (1) · Children's Oncology Group (1) · Duke University (1) · Fox Chase Cancer Center (1) · Healx Limited (1) · M.D. Anderson Cancer Center (1) · Radboud University Medical Center (1) · Stony Brook University (1) · University of Utah (1)
United States (14) · Australia (1) · Canada (1) · Ireland (1) · Netherlands (1)
Alison S Stopeck, MD (1) · Alison Stopeck, MD (1) · Amir Fathi, MD (1) · Elizabeth Berry-Kravis (1) · Fokko M Nagengast, PhD (1) · James Jett (1) · Jochen Lorch, MD (1) · John Crown, MD (1) · Mary Cianfrocca, DO (1) · Marybeth S Hughes, M.D. (1) · Niloy J Samadder, MD (1) · Patricia A Thompson-Carino, PhD (1) · Patricia Thompson-Carino, PhD (1) · Paul Limburg (1)
PMID 23261228, PMID 27002448, PMID 29423501, PMID 30012100, PMID 35039952
N01CN35000 (2), P30CA015083 (2), N01CN35158 (1), P01CA073992 (1), P30CA006927 (1), P30CA016672 (1), P30CA023074 (1), R01CA235677 (1), U10CA098543 (1)